Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and ...

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

In our “Why I’m Running” series, Boston Marathon athletes share what’s inspiring them to make the 26.2-mile trek from ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

In immune-mediated inflammatory diseases, the overall risk for serious adverse events is not notably higher with combo ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases; Initial data for NKX ...

Often skin changes are harmless and clear up on their own, but others can be warning signs of something more serious ...

Announcing a new publication for Acta Materia Medica journal. Kawasaki disease (KD) is a form of vasculitis that affects ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 11.16%, which has investors questioning if this is right time to ...